Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 May;24(5):628-637.
doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Andrew Tutt  1   2 , Holly Tovey  3 , Maggie Chon U Cheang  3 , Sarah Kernaghan  3 , Lucy Kilburn  3 , Patrycja Gazinska  4 , Julie Owen  5 , Jacinta Abraham  6 , Sophie Barrett  7 , Peter Barrett-Lee  6 , Robert Brown  8   9 , Stephen Chan  10 , Mitchell Dowsett  11   12 , James M Flanagan  8 , Lisa Fox  3 , Anita Grigoriadis  4 , Alexander Gutin  13 , Catherine Harper-Wynne  14 , Matthew Q Hatton  15 , Katherine A Hoadley  16 , Jyoti Parikh  17 , Peter Parker  18   19 , Charles M Perou  16 , Rebecca Roylance  20 , Vandna Shah  4 , Adam Shaw  21 , Ian E Smith  22 , Kirsten M Timms  13 , Andrew M Wardley  23 , Gregory Wilson  24 , Cheryl Gillett  5   25 , Jerry S Lanchbury  13 , Alan Ashworth  26 , Nazneen Rahman  27   28 , Mark Harries  29 , Paul Ellis  29 , Sarah E Pinder  5   25 , Judith M Bliss  3
Affiliations
Clinical Trial

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Andrew Tutt et al. Nat Med. 2018 May.

Abstract

Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs DNA lesions caused by platinum agents and PARP inhibitors. Triple-negative breast cancers (TNBCs) harbor subpopulations with BRCA1/2 mutations, hypothesized to be especially platinum-sensitive. Cancers in putative 'BRCAness' subgroups-tumors with BRCA1 methylation; low levels of BRCA1 mRNA (BRCA1 mRNA-low); or mutational signatures for HR deficiency and those with basal phenotypes-may also be sensitive to platinum. We assessed the efficacy of carboplatin and another mechanistically distinct therapy, docetaxel, in a phase 3 trial in subjects with unselected advanced TNBC. A prespecified protocol enabled biomarker-treatment interaction analyses in gBRCA-BC and BRCAness subgroups. The primary endpoint was objective response rate (ORR). In the unselected population (376 subjects; 188 carboplatin, 188 docetaxel), carboplatin was not more active than docetaxel (ORR, 31.4% versus 34.0%, respectively; P = 0.66). In contrast, in subjects with gBRCA-BC, carboplatin had double the ORR of docetaxel (68% versus 33%, respectively; biomarker, treatment interaction P = 0.01). Such benefit was not observed for subjects with BRCA1 methylation, BRCA1 mRNA-low tumors or a high score in a Myriad HRD assay. Significant interaction between treatment and the basal-like subtype was driven by high docetaxel response in the nonbasal subgroup. We conclude that patients with advanced TNBC benefit from characterization of BRCA1/2 mutations, but not BRCA1 methylation or Myriad HRD analyses, to inform choices on platinum-based chemotherapy. Additionally, gene expression analysis of basal-like cancers may also influence treatment selection.

PubMed Disclaimer

Conflict of interest statement

Competing Financial Interests

AT, HT, MC, SK, LK, PG, JO, RB, MD, LF, AG, PP, VS, CG, NR, SEP and JMB report grants to their institutional departments from Breast Cancer Now and/or Cancer Research UK, and other research support for costs or consumables in the study from Myriad Genetics, Inc. and NanoString Technologies, Inc. during the conduct of the study. In addition, AT has a patent PCT/EP2015/078987 pending on behalf of King’s College London.

MC has a patent “Gene expression profiles to predict relapse of breast cancer” filed in USA and elsewhere with royalties paid.

MD reports personal fees from Myriad outside the submitted work.

AGu reports salary compensation, and stock/options from Myriad Genetics Inc. during conduct of the study, and patent rights assigned to Myriad Genetics.

CMP reports personal fees from Bioclassifier LLC, other from Nanostring Technologies outside the submitted work. In addition, CMP has a patent U.S. Patent No. 9,631,239 with royalties paid.

KMT reports personal fees from Myriad Genetics, Inc. during the conduct of the study, and personal fees from Myriad Genetics, Inc. outside the submitted work. In addition, KT has the following patents pending: 13/164,499; 14/554,715; 15/010,721; 15/192,497; 14/245,576; 62/000,000; 62/311,231; 62/332,526; 14/962,588; 2802882; 11796544.2; 15189527.3; 2,839,210; 12801070.9; 2014-516031; 2012358244; 2,860,312; 201280070358.0; 12860530.0; 2014-548965; 2014248007; 2,908,745; 14779403.6; 2016-506657; 712,663; PCT/US15/045561; PCT/US15/064473; and the following patents issued to Myriad Genetics, Inc.: 9,279,156; 9,388,427 and 625468.

JSL reports salary compensation, and stock/options from Myriad Genetics Inc. during conduct of the study.

The other authors declare no competing interests.

Figures

Figure 1
Figure 1. Consort diagram
Flow of participants in the trial.
Figure 2
Figure 2. Response rates (overall and BRCA subgroups)
Absolute differences between treatment groups within biomarker subgroups are presented; p-values for the differences are calculated using a 2-sided Fisher’s exact test. P-values for interactions are based on a logistic regression model of response with terms for biomarker status, treatment group and interaction.
Figure 3
Figure 3. Progression-free survival (overall and BRCA subgroups)
Data presented is the difference in PFS restricted mean (95% CI). A negative value indicates a better response to docetaxel, positive values indicate better response to carboplatin. P-values are calculated using a 2-sided t-test comparing the mean survival between treatments (within biomarker groups as appropriate). C=Carboplatin; D=Docetaxel.
Figure 4
Figure 4. Response rates (HRD subgroups)
Absolute differences between treatment groups within HRD subgroups are presented; p-values for the differences are calculated using a 2-sided Fisher’s exact test. P-values for interactions are based on a logistic regression model of response with terms for biomarker status, treatment group and interaction.
Figure 5
Figure 5. Response rates (basal-like subgroups)
Absolute differences between treatment groups within basal subgroups are presented; p-values for the differences are calculated using a 2-sided Fisher’s exact test. P-values for interactions are based on a logistic regression model of response with terms for biomarker status, treatment group and interaction.
Figure 6
Figure 6. PFS (basal-like subgroups)
Data presented is the difference in PFS restricted mean within subgroups (95% CI). A negative value indicates a better response to docetaxel, positive values indicate better response to carboplatin. P-values are calculated using a 2-sided t-test comparing the mean survival between treatments within biomarker groups. C=Carboplatin; D=Docetaxel.
See this image and copyright information in PMC

Comment in

References

    1. Kassam F, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clinical breast cancer. 2009;9:29–33. doi: 10.3816/CBC.2009.n.005. - DOI - PubMed
    1. Sorlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:10869–10874. doi: 10.1073/pnas.191367098. - DOI - PMC - PubMed
    1. Curtis C, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–352. doi: 10.1038/nature10983. - DOI - PMC - PubMed
    1. Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation. 2011;121:2750–2767. doi: 10.1172/JCI45014. - DOI - PMC - PubMed
    1. Lehmann BD, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PloS one. 2016;11:e0157368. doi: 10.1371/journal.pone.0157368. - DOI - PMC - PubMed

Publication types